Kairos Pharma, Ltd
Financing
SEC filings to 2026-10-05 · every row opens its filingNewest
$75.0M
S-3 of 2026-01-13. Sales under the at-the-market programme filed with it are not stated apart. S-3 ↗
$4.5M
H.C. Wainwright, agreement of 2026-01-13. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗
Warrants
The 10-Q filed 2026-08-12 is not read yet.
Cash
2.6 quarters
$2.6M on 2026-06-30 ÷ $993K a quarter of operating cash used, the average of four quarters. 10-Q ↗
Raised: 6 of its filings are not read yet.
Also on file: a 1-for-3 reverse split, 2026-09-01 8-K ↗